Objective <p>This narrative review aims to comprehensively summarize the clinical application, combined therapeutic regimens, safety profile and research progress of triamcinolone acetonide in the treatment of oral submucous fibrosis (OSF).</p> Methods <p>For the literature used for this narrative review, a structured search was performed across the following databases: CNKI, Scopus, PubMed, Web of Science, Embase, Cochrane Library. Search terms included combinations of keywords and Medical Subject Headings (MeSH) such as: “oral submucous fibrosis”, “triamcinolone acetonide”, “glucocorticoid”, “intralesional”, “anti-inflammatory”, “combination therapy”, “Salvia miltiorrhiza Bunge”, “hyaluronidase”, “treatment outcome”, and “adverse reactions”. Boolean operators (AND/OR) were used to optimize the search strategy.</p> Result <p>Triamcinolone acetonide serves as a core agent for OSF, mainly administered via intralesional injection. Monotherapy achieves satisfactory symptomatic relief but presents high recurrence and limited efficacy in moderate‑to‑severe cases. Combined regimens with salvia miltiorrhiza, hyaluronidase, laser or physical therapy significantly enhance therapeutic outcomes. Staged administration ensures favorable safety with controllable local adverse events, though standardized protocols and high‑quality trials are still warranted.</p> Conclusion <p>Over time, as the clinical application of triamcinolone acetonide for OSF has evolved from simple monotherapy to standardized combined and staged regimens, research attention has shifted toward optimizing therapeutic protocols, improving long-term prognosis, reducing adverse reactions and lowering the risk of malignant transformation.</p>